Literature DB >> 8944568

Cost effectiveness of detecting Barrett's cancer.

T A Wright1, M R Gray, A I Morris, I T Gilmore, A Ellis, H L Smart, M Myskow, J Nash, R J Donnelly, A N Kingsnorth.   

Abstract

BACKGROUND: Screening Barrett's oesophagus is controversial owing to a large variation in the reported incidence of neoplastic change and lack of evidence that screening improves tumour prognosis. AIMS: To determine the incidence of Barrett's cancer, its cost of detection, and stage of disease at time of diagnosis. PATIENTS AND METHODS: Data from our surveillance programme have been reviewed to assess the incidence of malignant change, tumour stage at diagnosis, and the cost per cancer detected.
RESULTS: 166 patients had annual endoscopic surveillance. Six patients (five men) developed cancer-an incidence of one cancer per 59 male and 167 female patient-years of follow up. The screened group had a significantly earlier stage than a control group of unscreened cancers (p < 0.05). The cost of detecting one cancer was Pounds 14 868 for men and Pounds 42 084 for women.
CONCLUSIONS: The cost of screening for Barrett's cancer is high but may be justified on the basis of the high incidence of detecting early stage disease.

Entities:  

Mesh:

Year:  1996        PMID: 8944568      PMCID: PMC1383272          DOI: 10.1136/gut.39.4.574

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  36 in total

1.  The incidence of adenocarcinoma in columnar-lined (Barrett's) esophagus.

Authors:  A J Cameron; B J Ott; W S Payne
Journal:  N Engl J Med       Date:  1985-10-03       Impact factor: 91.245

2.  Carcinoma arising in Barrett's esophagus.

Authors:  H Sanfey; S R Hamilton; R R Smith; J L Cameron
Journal:  Surg Gynecol Obstet       Date:  1985-12

3.  Adenocarcinoma and Barrett's esophagus. An overrated risk?

Authors:  S J Spechler; A H Robbins; H B Rubins; M E Vincent; T Heeren; W G Doos; T Colton; E M Schimmel
Journal:  Gastroenterology       Date:  1984-10       Impact factor: 22.682

4.  Analysis of adenocarcinoma in Barrett's esophagus utilizing a staging system.

Authors:  J C Rosenberg; H Budev; R C Edwards; S Singal; Z Steiger; A S Sundareson
Journal:  Cancer       Date:  1985-03-15       Impact factor: 6.860

5.  Adenocarcinoma complicating columnar epithelium-lined (Barrett's) esophagus.

Authors:  R C Haggitt; J Tryzelaar; F H Ellis; H Colcher
Journal:  Am J Clin Pathol       Date:  1978-07       Impact factor: 2.493

6.  Adenocarcinoma in Barrett's esophagus after elimination of gastroesophageal reflux.

Authors:  S R Hamilton; D F Hutcheon; W J Ravich; J L Cameron; M Paulson
Journal:  Gastroenterology       Date:  1984-02       Impact factor: 22.682

7.  Barrett's esophagus. Comparison of benign and malignant cases.

Authors:  D B Skinner; B C Walther; R H Riddell; H Schmidt; C Iascone; T R DeMeester
Journal:  Ann Surg       Date:  1983-10       Impact factor: 12.969

8.  Columnar-lined lower esophagus: an acquired lesion with malignant predisposition. Report on 140 cases of Barrett's esophagus with 12 adenocarcinomas.

Authors:  A P Naef; M Savary; L Ozzello
Journal:  J Thorac Cardiovasc Surg       Date:  1975-11       Impact factor: 5.209

9.  Barrett's esophagus. Functional assessment, proposed pathogenesis, and surgical therapy.

Authors:  C Iascone; T R DeMeester; A G Little; D B Skinner
Journal:  Arch Surg       Date:  1983-05

10.  Cost-effectiveness model for colon cancer screening.

Authors:  D A Lieberman
Journal:  Gastroenterology       Date:  1995-12       Impact factor: 22.682

View more
  27 in total

1.  An evidence-based appraisal of reflux disease management--the Genval Workshop Report.

Authors: 
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Barrett's oesophagus: the continuing conundrum.

Authors:  T J McGarrity
Journal:  BMJ       Date:  2000-11-18

3.  Impact of endoscopic biopsy surveillance of Barrett's oesophagus on pathological stage and clinical outcome of Barrett's carcinoma.

Authors:  J W van Sandick; J J van Lanschot; B W Kuiken; G N Tytgat; G J Offerhaus; H Obertop
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

4.  Antagonist: endoscopic surveillance of patients with Barrett's oesophagus.

Authors:  R J Playford
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

5.  Chemoprevention of esophageal adenocarcinoma.

Authors:  Julian A Abrams
Journal:  Therap Adv Gastroenterol       Date:  2008-07       Impact factor: 4.409

Review 6.  Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.

Authors:  Kavel Visrodia; Siddharth Singh; Rajesh Krishnamoorthi; David A Ahlquist; Kenneth K Wang; Prasad G Iyer; David A Katzka
Journal:  Gastroenterology       Date:  2015-11-24       Impact factor: 22.682

Review 7.  Are screening and surveillance for Barrett's oesophagus really worthwhile?

Authors:  P Sharma; E I Sidorenko
Journal:  Gut       Date:  2005-03       Impact factor: 23.059

8.  Surveillance in Barrett's esophagus: an audit of practice.

Authors:  Adewale Ajumobi; Khaled Bahjri; Christian Jackson; Ronald Griffin
Journal:  Dig Dis Sci       Date:  2009-08-11       Impact factor: 3.199

9.  Risk of malignant progression in Barrett's esophagus patients: results from a large population-based study.

Authors:  Shivaram Bhat; Helen G Coleman; Fouad Yousef; Brian T Johnston; Damian T McManus; Anna T Gavin; Liam J Murray
Journal:  J Natl Cancer Inst       Date:  2011-06-16       Impact factor: 13.506

10.  Risk of oesophageal cancer in Barrett's oesophagus and gastro-oesophageal reflux.

Authors:  M Solaymani-Dodaran; R F A Logan; J West; T Card; C Coupland
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.